During the past decade, University of Miami Crohn's and Colitis Center conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 4 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Miami Crohn's and Colitis Center" #1 sponsor was "Galapagos NV" with 4 trials, followed by "Gilead Sciences" with 3 trials sponsored, "Landos Biopharma Inc." with 1 trials sponsored, "PredictImmune Ltd" with 1 trials sponsored and "Shire" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Miami Crohn's and Colitis Center" #1 collaborator was "Gilead Sciences" with 4 trials as a collaborator, "Galapagos NV" with 3 trials as a collaborator, "Crohn's and Colitis Foundation" with 1 trials as a collaborator and "Takeda" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "University of Miami Crohn's and Colitis Center" are "Ulcerative Colitis" (4 trials), "Crohn's Disease" (3 trials), "Crohn Disease" (2 trials), "Fistulizing Crohn's Disease" (1 trials) and "IBD" (1 trials). Many other conditions were trialed in "University of Miami Crohn's and Colitis Center" in a lesser frequency.

Most popular intervention types in "University of Miami Crohn's and Colitis Center" are "Drug" (10 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Filgotinib" (7 trials), "Placebo" (4 trials), "Placebo to match filgotinib" (3 trials), "NX-13 250mg IR" (1 trials) and "NX-13 500mg IR" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Miami Crohn's and Colitis Center" are 10 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of Miami Crohn's and Colitis Center". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 7 completed trials in University of Miami Crohn's and Colitis Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of Miami Crohn's and Colitis Center, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".